English
Armenian
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hungarian
Icelandic
Italian
Latvian
Lithuanian
Macedonian
Norwegian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Turkish
Prothena announces discontinuation of AL amyloidosis drug NEOD001
Prothena Corporation, a pharmaceutical company in neuroscience and orphan disease, has announced that it is discontinuing development of NEOD001, a drug being researched in clinical trials for the treatment of AL amyloidosis patients. The decision was taken because NEOD001 did not do as well as expected in its clinical development programme.